# US 2026/0085091 A1 · PEPTIDES THAT SELECTIVELY BIND TO Trop2 AND USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085091 A1
- Document ID: US20260085091A1
- Status: Published application
- Kind: A1
- Application number: 19/107,750
- Filed: 2023-08-10
- Published: 2026-03-26
- Earliest claimed: 2022-08-31
- Assignees: Kyungpook National University Industry-Academic Cooperation Foundation; Mahidol University
- Applicants: Kyungpook National University Industry-Academic Cooperation Foundation; Mahidol University
- Inventors: Byung-Heon LEE; Uttapol PERMPOON; Peti Thuwajit
- Web page: https://patentgrep.com/patent/US20260085091A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61P 35/00: Antineoplastic agents
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to a peptide binding to Trop 2 and a use thereof, wherein, in an attempt to find a peptide having an ability of specifically binding to Trop 2, a peptide (amino acid sequence: CSTLNVESC (SEQ ID NO: 1)) that selectively binds to Trop 2 was discovered using a phage display technique. Targeting cancers that are highly resistant to anticancer drugs in breast cancer (in particular, triple-negative breast cancer), pancreatic cancer, and cholangiocarcinoma while having no effective treatments, an effective anticancer drug may be prepared by delivering cancer-specific drugs or developing targeted therapeutic agents using the peptide of the present disclosure.

## Claims

### Claim 1

A peptide which has an amino acid sequence represented by SEQ ID NO: 1 and specifically binds to trophoblast antigen 2 (Trop2).

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

A method of diagnosing a cancer in a subject, comprising:
reacting the peptide of claim 1 with a tissue or cell obtained from the subject and
detecting the binding of the peptide to Trop2.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cancer is a cancer with a high expression level of Trop2.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cancer is any one or more selected from the group consisting of breast cancer, triple-negative breast cancer, lung cancer, pancreatic cancer, brain tumor, liver cancer, esophageal cancer, kidney cancer, colorectal cancer, rectal cancer, stomach cancer, thyroid cancer, bladder cancer, ovarian cancer, cholangiocarcinoma, bile duct cancer, gallbladder cancer, uterine cancer, cervical cancer, prostate cancer, head and neck cancer, laryngeal cancer, and oral cavity cancer.

### Claim at position 6

8-12. (canceled)

### Claim 13

A method of preventing or treating a cancer, comprising administering a pharmaceutical composition comprising a fusion peptide as an active ingredient in a subject,
wherein the fusion peptide comprises a peptide having an amino acid sequence represented by SEQ ID NO: 1 specifically binding to trophoblast antigen 2 (Trop2), a cell-permeable peptide having an amino acid sequence represented by SEQ ID NO: 2, and a proapoptotic peptide having an amino acid sequence represented by SEQ ID NO: 3.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cancer is a cancer with a high expression level of Trop2.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cancer is any one or more selected from the group consisting of breast cancer, triple-negative breast cancer, lung cancer, pancreatic cancer, brain tumor, liver cancer, esophageal cancer, kidney cancer, colorectal cancer, rectal cancer, stomach cancer, thyroid cancer, bladder cancer, ovarian cancer, cholangiocarcinoma, bile duct cancer, gallbladder cancer, uterine cancer, cervical cancer, prostate cancer, head and neck cancer, laryngeal cancer, and oral cavity cancer.

### Claim at position 10

16-17. (canceled)

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the peptide of claim 1.
